Stay updated on Gemcitabine Cisplatin Nivolumab in Bladder Sparing Clinical Trial
Sign up to get notified when there's something new on the Gemcitabine Cisplatin Nivolumab in Bladder Sparing Clinical Trial page.

Latest updates to the Gemcitabine Cisplatin Nivolumab in Bladder Sparing Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no visible edits to core study data, eligibility criteria, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision: v3.4.1 is listed, replacing v3.4.0, with no substantive study content changed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded a Show glossary option and updated QC-related labels to 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. Removed the previous items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check42 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check63 days agoChange DetectedA new consolidated Locations section has been added with state listings (California, New York, Oregon, Pennsylvania, Utah, Wisconsin) and the previous separate state location headings have been removed. This improves visibility of where the study is conducted.SummaryDifference0.7%

- Check92 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2. This is a minor maintenance update that does not change the study details.SummaryDifference0.1%

Stay in the know with updates to Gemcitabine Cisplatin Nivolumab in Bladder Sparing Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gemcitabine Cisplatin Nivolumab in Bladder Sparing Clinical Trial page.